Prebiotics and Probiotics: An Assessment of Their Safety and Health Benefits

Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion

Volumn , Issue , 2016, Pages 3-23

  Anadón, Arturo ^a   Martínez Larrañaga, María Rosa ^a   Arés, Irma ^a   Martínez, María Aránzazu ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Assessment; Efficacy; Prebiotics; Probiotics; QPS concept; Safety; Toxicity

Indexed keywords

EID: 84967012406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802189-7.00001-0     Document Type: Chapter

References (75)

1. Adams M.R., Marteau P. On the safety of lactic acid bacteria from food. Int. J. Food Microbiol. 1995, 27:263-264.
2. Aguirre M., Collins M.D. Lactic acid bacteria and human clinical infection. J. Appl. Bacteriol. 1993, 75:95-107.
3. Anadón A., Martinez-Larrañaga M.R., Martinez M.A. Probiotics for animal nutrition in the European Union. Regulation and safety assessment. Regul. Toxicol. Pharmacol. 2006, 45:91-95.
4. Anadón A., Castellano V., Martínez-Larrañaga M.R. Regulation and guidelines of probiotics and prebiotics. Probiotics and Prebiotics in Food, Nutrition and Health 2014, 91-113. CRC Press, LLC Taylor & Francis Group, Boca Raton, FL, USA. S. ötles (Ed.).
5. Anonymous Scientific concepts of functional foods in Europe. Consensus document. Br. J. Nutr. 1999, 81(Suppl.):S1-S27.
6. Blaut M. Relationship of prebiotics and food to intestinal microflora. Eur. J. Nutr. 2002, 41(Suppl. 1):S11-S16.
7. Bounik Y., Raskine L., Simoneau G., Vicaut E., Neut C., Flourie B., Brouns F., Bournet F.R. The capacity of non-digestible carbohydrates to stimulate fecal bifidobacteria in health humans: A double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am. J. Clin. Nutr. 2004, 80:1658-1664.
8. Butler R.N. Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy of biologics including prebiotics and probiotics. Curr. Pharm. Des. 2008, 14:1341-1350.
9. Cassidy A., Bingham S.A., Cummings J.H. Starch intake and colorectal cancer risk. An international comparison. Br. J. Cancer 1994, 69:119-125.
10. Cherbur C. Inulin and oligofructose in the dietary fiber concept. Br. J. Nutr. 2002, 87:159-162.
11. Cherbut C., Michel C., Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J. Nutr. 2003, 133:21-27.
12. Chow J. Probiotics and prebiotics. A brief overview. J. Ren. Nutr. 2002, 12:76-86.
13. Clausen M.R., Jorgensen J., Mortensen P.B. Comparison of diarrhea induced by ingestion of fructooligosaccharide Idolax and disaccharide lactulose: role of osmolarity versus fermentation of malabsorbed carbohydrate. Dig. Dis. Sci. 1998, 43:2696-2707.
14. Conway P.L. Prebiotics and human health: the state-of-the-art and future perspectives. Scand. J. Nutr. 2001, 45:13-21.
15. Curragh H.J., Collins M.A. High levels of spontaneous drug resistance in Lactobacillus. J. Appl. Bacteriol. 1992, 73:31-36.
16. De Vrese M., Scherezenmeir J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008, 111:1-66.
17. Delzenne N.M. Oligosaccharides: state of the art. Proc. Nutr. Soc. 2003, 62:177-182.
18. Dhodapkar K.M., Henry N.K. Leuconostoc bacteremia in an infant with short-gut syndrome: case report and literature review. Mayo Clin. Proc. 1996, 71:1171-1174.
19. Donohue D., Salminen S., Marteau P. Safety of probiotic bacteria. Lactic Acid Bacteria 1998, 369-384. Marcel Dekker, New York. S. Salimnen, A. von Wright (Eds.).
20. Douglas L.C., Sanders M.E. Probiotics and prebiotics in dietetics practice. J. Am. Diet. Assoc. 2008, 108(3):510-521.
21. EFSA, 2005. EFSA Scientific Colloquium Summary Report. OPS Qualified Presumption of Safety of Micro-organisms in Food and Feed, 13-14 December 2004, Brussels, Belgium. ISBN 92-9199-012-4. http://www.efsa.eu.int/science/colloquium_series/no2_qps/948_en.html/.
22. EFSA, 2007. Scientific and technical guidance for the preparation and presentation of the application for authorisation of a health claim (Request no. EFSA-Q-2007-066).
23. FAO, 2007. FAO Technical Meeting on Prebiotics. Food Quality and Standards Service (AGNS), Food and Agriculture Organization of the United Nations (FAO), September 15-16, 2007.
24. FAO/WHO, 2002. Joint FAO/WHO Group report on drafting guidelines for the evaluation of probiotics in food, London, Ontario, Canada, April 30 and May 2002.
25. FDA, 2003. Guidance Interim Procedures for Qualified Health Claims in the Labelling of Conventional Human Food and Human Dietary Supplements.
26. Flamm G., Glinsmann W., Kristchevsky D., Prosky L., Roberfroid M. Inulin and oligofructose as dietary fiber: a review of the evidence. Crit. Rev. Food Sci. Nutr. 2001, 41:353-362.
27. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'Neil D.A., Macfarlane G.T. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005, 54:242-249.
28. Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infections. Bull. Inst. Pasteur 1994, 92:45-67.
29. Gibson G.R., Roberfroid M. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 1995, 125:1401-1412.
30. Gibson G.R., Wang X. Bifidogenic properties of different types of fructo-oligosaccharides. Food Microbiol. 1994, 11:491-498.
31. Gibson G.R., Saavedra J.M., Macfarlane S., Macfarlane G.T. Gastrointestinal microbial disease. Probiotics 2: Applications and Practical Aspects 1997, 10-39. Chapman and Hall, Andover. R. Fuller (Ed.).
32. Gibson G.R., Probert H.M., Van Loo J., Rastall R.A., Roberfroid M. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr. Res. Rev. 2004, 17:259-275.
33. Gibson G.R., McCartney A.L., Rastall R.A. Prebiotics and resistance to gastrointestinal infections. Br. J. Nutr. 2005, 93(Suppl. 1):S31-S34.
34. Gruber C., van Stuijvenberd M., Mosca F., Moro G., Chirico G., Braegger C.P., Riedler J., Boehm G., Wahn U. Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants. J. Allerg. Clin. Immunol. 2010, 126(4):791-797.
35. Guarner F. Prebiotics in inflammatory bowel disease. Br. J. Nutr. 2007, 98(Suppl. 1):S85-S89.
36. Hidaka H., Eida T., Takizawa T., Tokunaga T., Tashiro Y. Effects of fructooligosaccharides on intestinal flora and human health. Bifidobact. Microflora 1986, 5:37-50.
37. ILSI Europe, 1993. A scientific basis for regulations on pathogenic microorganisms in foods. Summary of a workshop held in May 1993 and organised by the Scientific Committee on Microbiology, ILSI Press.
38. Ishibashi N., Yamazaki S. Probiotics and safety. Am. J. Clin. Nutr. 2001, 73(Suppl.):465S-470S.
39. Ishiwa H., Iwata M. Drug resistance plasmids in Lactobacillus fermentum. J. Gen. Appl. Microbiol. 1980, 26:71-74.
40. Jonas D., Abtignac E., Antoine J.M., Classen H.G., Huggett A., Knudsen I., Mahler J., Ockhuizen T., Smith M., Teuber M., Walker R., de Vogel D. The safety assessment of novel foods. Guidelines prepared by ILSI Europe novel foods task force. Food Chem. Toxicol. 1996, 34:931-940.
41. Kalliomaki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001, 357:1076-1079.
42. Kelly D., Conway S., Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol. 2005, 26:326-333.
43. Kohmoto T., Fukui F., Takaku H., Machida Y., Arai M., Mitsuoka T. Effect of isomalto-oligosaccharides on human fecal flora. Bifidobact. Microflora 1988, 1:61-68.
44. Kruger C.L., Mann S.W. Safety evaluation of functional ingredients. Food Chem. Toxicol. 2003, 41:793-805.
45. Marteau P., Boutron-Ruault M.C. Nutritional advantages of probiotics and prebiotics. Br. J. Nutr. 2002, 87(Suppl. 2):S153-S157.
46. Marteau P., Flourie B. Tolerance to low-digestible carbohydrates: symptomatology and methods. Br. J. Nutr. 2001, 85(Suppl. 1):S17-S21.
47. Marteau P., Pochart P., Bouhnik Y., Rambaud J.C. Fate and effects of some transiting microorganisms in the human gastrointestinal tract. World Rev. Nutr. Diet. 1993, 74:1-21.
48. Mäyrä-Mäkien A., Bigret M. Industrial use and production of lactic acid bacteria. Lactic Acid Bacteria 1993, 65-95. Marcel Dekker, New York. S. Salminen, A. von Wright (Eds.).
49. Mitsuoka T. Bifidobacteria and their role in human health. J. Ind. Microbiol. 1990, 6:263-268.
50. Mitsuoka T., Hidaka H., Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Nahrung 1987, 31:5-6.
51. Noonan W.P., Noonan C. Legal requirements for 'functional food' claims. Toxicol. Lett. 2004, 150:19-24.
52. Nyman M. Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose. Br. J. Nutr. 2002, 87:163-168.
53. Oli M.W., Petschow B.W., Buddington R.K. Evaluation of fructooligosaccharide supplementation of oral electrolyte solutions for treatment of diarrhea. Recovery of the intestinal bacteria. Dig. Dis. Sci. 1998, 43:138-147.
54. Ouwehand A.C., Salminen S., Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 2002, 82:279-289.
55. Przyrembel H. Consideration of possible legislation within existing regulatory frameworks. Am. J. Clin. Nutr. 2001, 73(Suppl.):471S-475S.
56. Rafter J.J. Scientific basis of biomarkers and benefits of functional foods for reduction of disease risk: cancer. Br. J. Nutr. 2002, 88:S219-S224.
57. Rao A.V. Dose-response effects of inulin and oligofructose and intestinal bifidogenesis effects. J. Nutr. 1999, 129(7S):1442S-1445S.
58. Rautava S., Luoto R., Salminen S., Isolauri E. Microbial contact during pregnancy, intestinal colonization and human disease. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:565-576.
59. Rautio M., Jousumies-Somer H., Kauma H., Pietarinen I., Saxelin M., Tynkkynen S., Koskela M. Liver abscess due to a Lactobacillus rhamnosus strain GG. Clin. Infect. Dis. 1999, 28:1159-1160.
60. Reid G., Bruce A.W., Fraser N., Heinemann C., Owen J., Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol. Med. Microbiol. 2001, 30:49-52.
61. Roberfoid M., Slavin J. Nondigestible oligosaccharides. Crit. Rev. Food Sci. Nutr. 2000, 40:461-480.
62. Roberfroid M. Prebiotics: the concept revisited. J. Nutr. 2007, 137:830-837.
63. Ross Products Division Ross Medical Nutrition Pocket Guide 2005, Abbot Laboratories, Columbus, OH.
64. Salminen S., von Wright A. Current probiotics-safety assured?. Microb. Ecol. Health Dis. 1998, 10:68-77.
65. Salminen S., von Wright A., Morelli L., Marteau P., Brassard D., de Vos W.M., Fondén R., Saxelin M., Collins K., Mogensen G., Birkeland S.E., Mattila-Sandholm T. Demonstration of safety of probiotics-a review. Int. J. Food Microbiol. 1998, 44:93-106.
66. SANCO (2002). Discussion Paper: Implementation of Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients, July 2002.
67. Sanders M.E., Tompkins T., Heimbach J., Kolida S. Weight of evidence needed to substantiate a health effect for probiotics and prebiotics. Regulatory considerations in Canada, E.U., and U.S. Eur. J. Nutr. 2005, 44:303-310.
68. Scholz-Ahrens K.E., Schaafama G., van den Heuvel E.G. Effects of prebiotics on mineral metabolism. Am. J. Clin. Nutr. 2001, 73(Suppl.):459S-464S.
69. Schultz M., Munro K., Tannock G.W., Melchner I., Gotti C., Scweietz H., Scholmerich J., Rath H.C. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. Clin. Diagn. Lab. Immunol. 2004, 11:581-587.
70. Seidner D.L., Lashner B.A., Brzezinski A., Banks P.L., Goldblum J., Fiocchi C., Katz J., Lichtenstein G.R., Anton P.A., Kam L.Y., Garleb K.A., Demichele S.J. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin. Gastroenterol. Hepatol. 2005, 3:358-369.
71. Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., Gordon J.I. The human microbiome project. Nature 2007, 449:804-810.
72. Wang X., Gibson G.R. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J. Appl. Bacteriol. 1993, 75:373-380.
73. Wolf B.W., Chow J.M., Garleb K.A. Medical foods and fructooligosaccharides. Polysaccharides: Structural Diversity and Functional Versatility 2005, 853-866. Marcel Dekker, New York. second ed. S. Dimitriu (Ed.).
74. Younes H., Garleb K., Behr S., Remesy C., Demigne C. Fermentable fibers or oligosaccharides reduce urinary nitrogen excretion by increasing urea disposal in the rat caecum. J. Nutr. 1995, 3:139-148.
75. Younes H., Alphonse J.C., Hadj-Adbelkader M., Remesy C. Fermentable carbohydrates and digestive nitrogen excretion. J. Ren. Nutr. 2001, 3:139-148.